PURPOSE: A large body of evidence suggests that being diagnosed with and treated for cancer adversely affects functioning and quality of life, yet less is known about longer term outcomes. Therefore, this study aims to estimate the prevalence of post-traumatic stress disorder (PTSD) symptoms in survivors of adult non-Hodgkin's lymphoma (NHL) who are at least 2 years postdiagnosis and identify the risk factors associated with PTSD symptoms, with a focus on those that are amenable for screening and modifiable. PATIENTS AND METHODS: A total of 886 NHL survivors identified from the cancer registries of two hospitals in North Carolina participated, ranging in age from 25 to 92 years old and ranging from 2 to 44 years postdiagnosis. Survivors were mailed a survey that assessed PTSD symptoms and quality of life. RESULTS: Participants averaged 10.2 years postdiagnosis, and most (61%) reported no PTSD symptoms. The adjusted prevalence for full PTSD was 7.9%, with an additional 9.1% meeting criteria for partial PTSD. Modifiable risk factors that were independently associated with PTSD in multiple linear regression included less social support, negative appraisals of life threat and treatment intensity, and more employment and insurance issues. Additionally, several demographic characteristics (nonwhite race, less education, and younger age) and clinical or health-related factors (active disease, more recent diagnosis, and more comorbidity) were independently associated with PTSD. CONCLUSION: Although only 8% of survivors met PTSD diagnostic criteria, the impact of a cancer diagnosis and treatment persists for many survivors, as evidenced in 39% of this sample. Early identification of those at risk could enable treatment to minimize PTSD symptomatology.
PURPOSE: A large body of evidence suggests that being diagnosed with and treated for cancer adversely affects functioning and quality of life, yet less is known about longer term outcomes. Therefore, this study aims to estimate the prevalence of post-traumatic stress disorder (PTSD) symptoms in survivors of adult non-Hodgkin's lymphoma (NHL) who are at least 2 years postdiagnosis and identify the risk factors associated with PTSD symptoms, with a focus on those that are amenable for screening and modifiable. PATIENTS AND METHODS: A total of 886 NHL survivors identified from the cancer registries of two hospitals in North Carolina participated, ranging in age from 25 to 92 years old and ranging from 2 to 44 years postdiagnosis. Survivors were mailed a survey that assessed PTSD symptoms and quality of life. RESULTS:Participants averaged 10.2 years postdiagnosis, and most (61%) reported no PTSD symptoms. The adjusted prevalence for full PTSD was 7.9%, with an additional 9.1% meeting criteria for partial PTSD. Modifiable risk factors that were independently associated with PTSD in multiple linear regression included less social support, negative appraisals of life threat and treatment intensity, and more employment and insurance issues. Additionally, several demographic characteristics (nonwhite race, less education, and younger age) and clinical or health-related factors (active disease, more recent diagnosis, and more comorbidity) were independently associated with PTSD. CONCLUSION: Although only 8% of survivors met PTSD diagnostic criteria, the impact of a cancer diagnosis and treatment persists for many survivors, as evidenced in 39% of this sample. Early identification of those at risk could enable treatment to minimize PTSD symptomatology.
Authors: A B Kornblith; J Anderson; D F Cella; S Tross; E Zuckerman; E Cherin; E Henderson; R B Weiss; M R Cooper; R T Silver Journal: Cancer Date: 1992-10-15 Impact factor: 6.860
Authors: Alice B Kornblith; Mark Powell; Meredith M Regan; Samantha Bennett; Carolyn Krasner; Beverly Moy; Jerry Younger; Annekathyrn Goodman; Ross Berkowitz; Eric Winer Journal: Psychooncology Date: 2007-10 Impact factor: 3.894
Authors: Anne E Kazak; Melissa A Alderfer; Randi Streisand; Steven Simms; Mary T Rourke; Lamia P Barakat; Paul Gallagher; Avital Cnaan Journal: J Fam Psychol Date: 2004-09
Authors: Alice B Kornblith; James E Herndon; Raymond B Weiss; Chunfeng Zhang; Enid L Zuckerman; Sylvia Rosenberg; Magriet Mertz; David Payne; Mary Jane Massie; James F Holland; Patti Wingate; Larry Norton; Jimmie C Holland Journal: Cancer Date: 2003-08-15 Impact factor: 6.860
Authors: Cécile Conte; Manuela Rueter; Guy Laurent; Robert Bourrel; Maryse Lapeyre-Mestre; Fabien Despas Journal: Support Care Cancer Date: 2016-07-19 Impact factor: 3.603
Authors: Neomi Vin-Raviv; Grace Clarke Hillyer; Dawn L Hershman; Sandro Galea; Nicole Leoce; Dana H Bovbjerg; Lawrence H Kushi; Candyce Kroenke; Lois Lamerato; Christine B Ambrosone; Heidis Valdimorsdottir; Lina Jandorf; Jeanne S Mandelblatt; Wei-Yann Tsai; Alfred I Neugut Journal: J Natl Cancer Inst Date: 2013-02-21 Impact factor: 13.506
Authors: Donna M Posluszny; Angela Liegey Dougall; Jonas T Johnson; Athanassios Argiris; Robert L Ferris; Andrew Baum; Dana H Bovbjerg; Mary Amanda Dew Journal: Head Neck Date: 2014-09-17 Impact factor: 3.147
Authors: Gita Thanarajasingam; Lori M Minasian; Frederic Baron; Franco Cavalli; R Angelo De Claro; Amylou C Dueck; Tarec C El-Galaly; Neil Everest; Jan Geissler; Christian Gisselbrecht; John Gribben; Mary Horowitz; S Percy Ivy; Caron A Jacobson; Armand Keating; Paul G Kluetz; Aviva Krauss; Yok Lam Kwong; Richard F Little; Francois-Xavier Mahon; Matthew J Matasar; María-Victoria Mateos; Kristen McCullough; Robert S Miller; Mohamad Mohty; Philippe Moreau; Lindsay M Morton; Sumimasa Nagai; Simon Rule; Jeff Sloan; Pieter Sonneveld; Carrie A Thompson; Kyriaki Tzogani; Flora E van Leeuwen; Galina Velikova; Diego Villa; John R Wingard; Sophie Wintrich; John F Seymour; Thomas M Habermann Journal: Lancet Haematol Date: 2018-06-18 Impact factor: 18.959
Authors: Catherine M Crespi; Sophia K Smith; Laura Petersen; Sheryl Zimmerman; Patricia A Ganz Journal: J Cancer Surviv Date: 2009-12-06 Impact factor: 4.442